Myasthenia gravis presenting with unusual neurogenic muscle atrophy

Muscle and Nerve

Volumn 36, Issue 3, 2007, Pages 394-399

  Samuraki, Miharu ^a   Furui, Eisuke ^a   Komai, Kiyonobu ^a   Takamori, Masaharu ^b   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b Kanazawa Nishi Hospital   (Japan)

Author keywords

Histochemical studies; Muscle atrophy; Myasthenia gravis; Neurogenic changes; Single fiber EMG

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; PREDNISOLONE;

ADULT; ARM MUSCLE; ARM WEAKNESS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; ELECTROMYOGRAPHY; EXTERNAL OPHTHALMOPLEGIA; HEREDITARY MOTOR SENSORY NEUROPATHY; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION DISORDER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ELECTROMYOGRAPHY; HUMANS; MALE; MUSCULAR ATROPHY; MYASTHENIA GRAVIS; OPHTHALMOPLEGIA;

EID: 34548205908     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20757     Document Type: Article

References (23)

1. Barbieri S, Weiss G, Daube J. Fibrillation potentials in myasthenia gravis. Muscle Nerve Suppl 9 1982;5:S50.
2. Benveniste O, Jacobson L, Farrugia ME, Clover L, Vincent A. MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. J Neuroimmunol 2005;170:41-48.
3. Bickerstaff ER, Evans JV, Woolf AL. Ultra-structure of the myoneural junction in myasthenia gravis. Nature 1959;184:1500.
4. Bickerstaff ER, Evans JV, Woolf AL. The ultrastructure of human myasthenic and non-myasthenic motor end plates. Brain 1960;83:638-647.
5. Brownell B, Oppenheimer DR, Spalding JM. Neurogenic muscle atrophy in myasthenia gravis. J Neurol Neurosurg Psychiatry 1972;35:311-322.
6. De Assis JL, Marchiori PE, Scaff M. Atrophy of the tongue with persistent articulation disorder in myasthenia gravis: report of 10 patients. Auris Nasus Larynx 1994;21:215-218.
7. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-2311.
8. Inatus A, Ohi T, Shioya K, Matsukura S. A case of myasthenia gravis occurring in the period of remission of chronic inflammatory demyelinating polyradiculoneuropathy. Rinsho Shinkeigaku 1992;32:878-879.
9. Ishii W, Matsuda M, Okamoto N, Shimojima Y, Yazaki M, Motomura M, et al. Myasthenia gravis with anti-MuSK antibody, showing progressive muscular atrophy without blepharoptosis. Intern Med 2005;44:671-672.
10. Kimura K, Nezu A, Kimura S, Otsuki N, Kobayashi T, Nomura Y, et al. A case of myasthenia gravis in childhood associated with chronic inflammatory demyelinating polyradiculoneuropathy. Neuropediatrics 1998;29:108-112.
11. Kinoshita M, Nakazato H, Wakata N, Satoyoshi E. Myasthenic neuromyopathy. An unusual neuromuscular disorder. Eur Neurol 1982;21:52-58.
12. Kurihara T. Seronegative myasthenia gravis and muscle atrophy of the tongue. Intern Med 2005;44:536-537.
13. Oosterhuis H, Bethlem J. Neurogenic muscle involvement in myasthenia gravis. A clinical and histopathological study. J Neurol Neurosurg Psychiatry 1973;36:244-254.
14. Oosterhuis H. Clinical aspects: examination of the myasthenic patient. In: Glaser GH, Barbeau A, Barnett HJM, Collins WT, Fenichel GM, Gillingham FJ, et al. editors. Myasthenia gravis. Edinburgh: Churchill Livingstone; 1984. p 29-42.
15. Osserman KE, Kornfeld P, Cohen E, Genkins G, Mendelow H, Goldberg H, et al. Studies in myasthenia gravis; review of two hundred eighty-two cases at the Mount Sinai Hospital, New York City. AMA Arch Intern Med 1958;102:72-81.
16. Pascuzzi RM, Campa JF. Lymphorrhage localized to the muscle end-plate in myasthenia gravis. Arch Pathol Lab Med 1988;112:934-937.
17. Restivo DA, Bianconi C, Ravenni R, De Grandis D. ALS and myasthenia: An unusual association in a patient treated with riluzole. Muscle Nerve 2000;23:294-295.
18. Russell DS. Histological changes in the striped muscles in myasthenia gravis. J Pathol Bacteriol 1953;65:279-289.
19. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004;62:1945-1950.
20. Stålberg E, Trontelj J. SFEMG phenomena and parameters. In: Stålberg E, Trontelj J, editors. Single fibre electromyography. Old Woking, UK: Miraville Press; 1979. p 67-69.
21. Tam DA, Chalmers A. Chronic inflammatory demyelinating polyneuropathy and myasthenia gravis. J Child Neurol 1999;14:478-479.
22. Tsujihata M, Yoshimura T, Satoh A, Kinoshita I, Matsuo H, Mori M, et al. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 1989;39:1359-1363.
23. Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Semin Neurol 2004;24:125-133.